Correction: The story has been updated to include the correct net proceed amount from the sale.

NEW YORK (GenomeWeb News) – Fluidigm said after the close of the market on Tuesday it has closed on the sale of about $201.3 million of senior convertible notes.

The sale was pursuant to an underwriting agreement between the South San Francisco, Calif.-based firm and Piper Jaffray. The notes are 2.75 percent senior convertible notes due in 2034.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.